LONDON — When Europe’s largest cardiology conference opened here this past Friday, one of the first sessions centered entirely on a single drug.
It cut the risk of complications from a common form of heart failure, researchers reported. It helped improve the structure of the heart as well as its function. It even saved the lives of people with Covid-19 — a respiratory infection of all things.
“Now on to something entirely different,” Richard Pratley, a diabetes specialist at AdventHealth in Orlando, told the standing-room-only crowd as he introduced a trial of the drug in kidney disease.
